Page 25 - Read Online

Daniele et al. Hepatoma Res 2021;7:61 https://dx.doi.org/10.20517/2394-5079.2021.58 Page 13 of 14

Financial support and sponsorship
The study was supported by the Italian Drug Agency (AIFA) in May 2011 (code FARM84SA2X) for trial
coordination activities.

Conflict of interest
Massimo Di Maio reports personal honoraria (for participation in meetings, advisory boards or for acting as
consultant) from Bristol Myers Squibb, Merck Sharp & Dohme, Pfizer, AstraZeneca, Eisai, Takeda, Janssen,
Astellas, and institutional research grant from Tesaro.
Antonio Frassoldati reports personal honoraria for advisory board from Novartis and Roche, invited
lectures Novartis, Pfizer, Lilly, AstraZeneca, Celgene.
Sandro Barni reports personal honoraria from Genomic Health, Bayer AG, Eli-Lilly, Roche, Italfarmaco,
Eisai, Astellas, Mylan, Leo Pharma, Pharmanutra, Medac Pharma, Kyowa Kirin.
Luigi Cavanna reports travel/Accomodations/meeting expenses from Pfizer, Ipsen, Celgene and personal
honoraria for consultancy from AstraZeneca, Merck.
Raffaella Tortora reports personal honoraria for advisory boards from Bayer and Abbvie.
Gennaro Daniele: reports personal honoraria for advisory board from Beigene, and travel support from
Roche.
Luigi Bolondi reports personal honoraria from Bayer, BMS, Sirtex, Guerbet, Alfa Sigma.
Francesco Perrone reports grants, personal fee and non-financial support from Bayer, grants and personal
fees from Incyte and Astra Zeneca, personal fees from Celgene, Sandoz, Pierre Fabre, Janssen Cilag, Roche,
and grants from Pfizer.
Maria Carmela Piccirillo reports personal fees from Daichii Sankyo, GSK, MSD, grants from Roche, grants
and personal fees from AstraZeneca, non-financial support from Bayer.
Bruno Daniele reports personal fees from Bayer, Eli Lilly, Ipsen, Astrazeneca, MSD; Sanofi Aventis, Roche,
personal fees and payment for lectures from Eisai.
The other authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
The study was promoted by the Istituto Nazionale per lo Studio e la Cura dei Tumori, IRCCS, Fondazione
G. Pascale, Napoli, Italy. The study was performed in accordance with the Declaration of Helsinki. Ethics
Committees at each participating Institution approved the study, and all the patients signed the informed
consent before any study related procedure.

Consent for publication
All the patients signed the informed consent before any study related procedure.

Copyright
© The Author(s) 2021.

REFERENCES
1. Cancer today - IARC database. Available from: https://gco.iarc.fr [Last accessed on 2 Aug 2021].
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA A Cancer J Clin 2018;69:7-34. DOI PubMed
3. new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program
(CLIP) investigators. Hepatology 1998;28:751-5. DOI PubMed
4. Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999;19:329-38.
DOI PubMed
5. validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. The Cancer of the
Liver Italian Program (CLIP) Investigators. Hepatology 2000;31:840-5. DOI PubMed
6. Lu LC, Shao YY, Chan SY, Hsu CH, Cheng AL. Clinical characteristics of advanced hepatocellular carcinoma patients with prolonged
survival in the era of anti-angiogenic targeted-therapy. Anticancer Res 2014;34:1047-52. PubMed
7. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK
pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-109. DOI PubMed